Indications |
Oral Advanced or locally advanced breast cancer, Adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer Adult: 2.5 mg once daily. Hepatic impairment: Reduce dose by 50% in patients with cirrhosis and severe hepatic impairment; recommended dose: 2.5 mg on alternate days. Special Populations: In renal failure: No dosage adjustment is required in patients with CrCl of at least 10 mL/min. In hepatic failure: No dosage adjustment is required in patients with mild to moderate hepatic impairment. Use with caution. |
Contraindications |
Premenopausal women and children; hypersensitivity. |
Warnings / Precautions |
Severe renal impairment; severe hepatic impairment; osteoporosis. Caution when driving or operating machinery. |
Adverse Reactions |
Hot flushes, arthralgia, nausea, vomiting, fatigue, dizziness, headache, dyspepsia, constipation, diarrhoea, anorexia, alopoecia, increased sweating, rash, peripheral oedema, osteoporosis, musculoskeletal pain, vaginal irritation. Potentially Fatal: Thromboembolic events. |
Drug Interactions |
Plasma levels reduced by tamoxifen. See Below for More letrozole Drug Interactions |
Mechanism of Actions |
Letrozole competitively binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgen to oestrogen, leading to inhibition of the enzyme and a significant reduction in plasma oestrogen levels. Absorption: Rapidly and completely absorbed from the GI tract. Distribution: Weakly bound to plasma proteins and has a large volume of distribution of about 1.9 l/kg. Metabolism: Slow hepatic metabolism to inactive metabolites. Excretion: Via urine (6% as unchanged drug); elimination half life of about 2 days. |
Administration |
May be taken with or without food. |
ATC Classification |
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in endocrine therapy. |
Available As |
|
Letrozole
Post Review about Letrozole Click here to cancel reply.
Letrozole Containing Brands
Letrozole is used in following diseases
Drug - Drug Interactions of Letrozole
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.